Literature DB >> 26854326

Intravenous busulfan dose individualization - impact of modeling approach on dose recommendation.

Susan M Abdel-Rahman1,2, K Leigh Casey3, Uttam Garg2,4, Jignesh Dalal5.   

Abstract

TDM is intended to limit unintended consequences of drugs with narrow therapeutic indices. However, the application of different sampling strategies and pharmacokinetic approaches results in different dosing recommendations and ostensibly different outcomes. TDM approaches for intravenous busulfan dose individualization employ compartmental or non-compartmental modeling with anywhere from three to seven drug levels. This investigation was designed to examine the differences in dosing recommendations that arise in children (n = 30) when five different TDM approaches were employed. Significant differences in recommended doses between modeling strategies were observed. More importantly, the recommendations were discordant in 13 cases with at least one model recommending a dose adjustment in the opposite direction relative to the remaining models. The mathematical differences introduced by the application of different TDM approaches are not purely academic. Unification of busulfan TDM approaches should be considered to mitigate inconsistently applied dose adjustment, and facilitate comparisons of outcome, between clinical centers.
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Food and Drug Administration; hematopoietic stem cell transplant; reference laboratory; therapeutic drug monitoring

Mesh:

Substances:

Year:  2016        PMID: 26854326     DOI: 10.1111/petr.12687

Source DB:  PubMed          Journal:  Pediatr Transplant        ISSN: 1397-3142


  3 in total

1.  Test Dose Pharmacokinetics in Pediatric Patients Receiving Once-Daily IV Busulfan Conditioning for Hematopoietic Stem Cell Transplant: A Reliable Approach?

Authors:  Kristina M Brooks; Paul Jarosinski; Thomas Hughes; Elizabeth Kang; Nirali N Shah; John B Le Gall; Dennis D Hickstein; Suk See De Ravin; Jomy M George; Parag Kumar
Journal:  J Clin Pharmacol       Date:  2017-12-14       Impact factor: 3.126

2.  Precision dosing to avoid adverse drug reactions.

Authors:  Thomas M Polasek; Carl M J Kirkpatrick; Amin Rostami-Hodjegan
Journal:  Ther Adv Drug Saf       Date:  2019-12-11

3.  Design and Testing of an EHR-Integrated, Busulfan Pharmacokinetic Decision Support Tool for the Point-of-Care Clinician.

Authors:  Susan M Abdel-Rahman; Matthew L Breitkreutz; Charlie Bi; Brett J Matzuka; Jignesh Dalal; K Leigh Casey; Uttam Garg; Sara Winkle; J Steven Leeder; JeanAnn Breedlove; Brian Rivera
Journal:  Front Pharmacol       Date:  2016-03-30       Impact factor: 5.810

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.